genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Artificial Intelligence
One AI Tool Bests Another in Enzyme Prediction Match
Cancer
How Incurable Melanoma Resists Treatment
AgBio
Food For Thought: Final Report from the AGBT Ag Meeting
Cancer
Molecular Time Travel Helps Colon Cells Turn Cancerous
Autism
Amino Acid Deficit Impacts Perinatal Mouse Brain Development, Leading to Microcephaly,…
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Base Editing
One-Time Treatment: Base Editing Shows Promise vs. SMA
Drug Delivery
Nature’s Needle: Feng Zhang’s Team Re-engineers Bacterial “Syringes” for Programmable Protein…
Bioprocessing
Polymer Formulation to Improve Existing Antibiotics
Bioprocessing
Key Consideration for Going Digital
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
T Cells
CAR T-Cells
CAR T-Cells
CAR T-Cells
Dendritic Cells
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
On Demand Webinars
Data-Driven Insights on Cell Therapy Fill and Finish Processes
CAR T-Cells
Cell Therapy Manufacturing: The Supply Chain Challenge
CAR T-Cells
Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition
CAR T-Cells
Coronado Inks Deal with NeuPharma, Creates New Company with City of Hope
CAR T-Cells
CAR-Engineered Blood Stem Cells Offer New Hope for Long-Term HIV Gene Therapy
CAR T-Cells
Regeneron to Invest $100M in bluebird bio as Companies Partner in...
CAR T-Cells
3D Bioscaffold Mimics Antigen-Presenting Cells for Improved T-Cell Expansion
CAR T-Cells
Identification of Sprouty 1 and Sprouty 2 Provide Basis for New...
CAR T-Cells
Cancer Immunotherapy Channeled via Remote Control
CAR T-Cells
Novartis Eliminates Cell & Gene Therapies Unit, Restates CAR T-Cell Commitment
CAR T-Cells
Novel Biomaterials Boost T-Cell Production
CAR T-Cells
Two More Deaths Reported in Juno Car-T Trial
CAR T-Cells
Human CAR-T Cell Glioblastoma Trial Generates Clues for Improving Treatment
CAR T-Cells
Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma
CAR T-Cells
CAR T-Cell Immunotherapy Proves a Plus in Treatment-Resistant Chronic Lymphocytic Leukemia
1
2
3
...
16
Page 1 of 16
Scroll Up
![Sangamo Therapeutics aims to position itself as a leader in the development of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) cell therapies for immunological diseases with its planned acquisition of TxCell. [Source: TxCell]](https://www.genengnews.com/wp-content/uploads/2018/08/ENTrIA_recognition_EN_without_entria1024x9291472362223-265x198.png "Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition")
![Regeneron Pharmaceuticals demonstrated its VelocImmune technology in a study published in 2015 in Proceedings of the National Academy of Sciences showing the rapid generation of fully human neutralizing antibodies against Middle East Respiratory Syndrome coronavirus (MERS-CoV) and development of a humanized mouse model for MERS-CoV infection (pictured). Regeneron will use VelocImmune and other VelociSuite platform technologies in a collaboration with bluebird bio to develop new immune cell therapies for cancer. [Source: PNAS]](https://www.genengnews.com/wp-content/uploads/2018/08/F7large2321726613-324x160.jpg "Regeneron to Invest $100M in bluebird bio as Companies Partner in Cancer Therapies")
